The DC-targeted vaccine oxidized mannan-MUC-1 dramatically decreased the recurrence rate in 31 patients with breast cancer (12.5% vs. 60% in patients who received placebo) at 15 years of follow-up [39]. Here, MUC1 is linked to breast carcinoma.